The Food and Drug Administration (FDA)
has proposed a voluntary procedure whereby manufacturers would
notify FDA about a view that a particular use (or uses) of a
substance is not subject to the statutory premarket approval
requirements based on a conclusion that such use is generally
recognized as safe (GRAS). The proposed regulations (proposed 21
CFR 170.36 (# 170.36)) and 21 CFR 570.36 (# 570.36) would provide a
standard format for the voluntary submission of a notice.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.